InterMune Inc. Third Quarter Earnings Sneak Peek

InterMune, Inc. (NASDAQ:ITMN) will unveil its latest earnings on Thursday, November 3, 2011. InterMune is a biotech company, which is focused on developing and commercializing innovative therapies in pulmonology and hepatology.

InterMune, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 73 cents per share, a wider loss from the year earlier quarter net loss of 44 cents. During the past three months, the average estimate has moved down from a loss of 68 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at a loss of 73 cents during the last month.

Past Earnings Performance: The company fell short of estimates last quarter after topping forecasts the quarter prior. In the second quarter, it reported a loss of 68 cents per share against a mean estimate of 61 cents. Two quarters ago, it beat expectations by 21 cents with net loss of 57 cents.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Wall St. Revenue Expectations: On average, analysts predict $5.4 million in revenue this quarter, a decline of 3.9% from the year ago quarter. Analysts are forecasting total revenue of $26.7 million for the year, a decline of 89.7% from last year’s revenue of $259.3 million.

Analyst Ratings: Analysts are bullish on this stock with 12 analysts rating it as a buy, one rating it as a sell and one rating it as a hold.

A Look Back: In the second quarter, the company’s loss widened to a loss of a $39.9 million (68 cents a share) from a loss of $25.3 million (46 cents) a year earlier, missing analyst expectations. Revenue rose 5.9% to $6.2 million from $5.9 million.

Competitors to Watch: Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Amgen, Inc. (NASDAQ:AMGN), Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Pharmasset, Inc. (NASDAQ:VRUS) and Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS).

Stock Price Performance: During September 30, 2011 to October 28, 2011, the stock price had risen $5.96 (29.5%) from $20.20 to $26.16. The stock price saw one of its best stretches over the last year between February 9, 2011 and February 16, 2011 when shares rose for six-straight days, rising 5.2% (+$1.89) over that span. It saw one of its worst periods between November 17, 2010 and November 30, 2010 when shares fell for nine-straight days, falling 8.9% (-$1.23) over that span. Shares are down $10.24 (-28.1%) year to date.

(Source: Xignite Financials)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.